Skip to content

Author

Eric Ubil

We have 2 of 18 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Targeting Pros1 to improve chemotherapy efficacy and immune anti-tumor response 2309304

A novel mechanism through which cancer cells promote Pros1 expression in response to chemotherapy is identified, and a better understanding of the mechanisms that regulate Pros1 expression may allow us to increase the efficacy of conventional therapies in melanoma patients.

Nestor Prieto-Dominguez, Oluwaseyi Omodiminiyi, Eric Ubil · 0 citations
Jul 2026

Increasing the Efficacy of Chemotherapy by Rescuing the Innate Immune Response 2309649

Despite advancements in immunotherapy, more than half of melanoma patients will either not respond or will later relapse after treatment with immune checkpoint blockade (ICB). For later-stage patients, chemotherapy is an essential treatment modality, but tumor intrinsic cell survival mechanisms and an immunosuppr...

Oluwaseyi Omodiminiyi, Nestor Prieto-Dominguez, Eric Ubil · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.